stocktools
Dilution profile // every instrument, one screen, from SEC filings

BRIGHT MINDS BIOSCIENCES INC. (DRUG)

CIK 1827401 · all EDGAR filings →

Overall dilution risk
HIGHworst of 2 computed signals (offering ability)
= the worst band among the computed sub-ratings, no hidden weighting
not every sub-rating was computable; treat as a floor
Offering ability
HIGH$250M registered
= total registered offering amount from the fee exhibits of live registrations (bands: $1M / $20M)
one or more live registrations had no structured fee data, so the true total is AT LEAST this
Overhead supply
NOT COMPUTEDno warrant count tagged in XBRL
= warrant shares outstanding divided by current shares outstanding
absence of a tag is not proof of absence of warrants
Historical dilution
LOW-62% O/S in 3y
= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative
a reverse-split-sized cliff is in this window; read the chart
Cash need
NOT COMPUTEDrunway not computable from latest facts
= cash vs trailing operating burn

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

2021-09-302024-09-30

Latest: 4.5M shares as of Sep 30, 2024 (20-F). Share count fell from 17.6M to 4.5M between Sep 30, 2022 and Sep 30, 2023, a pattern consistent with a reverse split (roughly 1-for-4); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.

Cash runway

Not enough filing data

can’t compute a runway

Full breakdown: cash runway tool

Warrants

No warrant figures tagged in this filer’s XBRL facts. That means the company has not reported them in structured form; it does not prove no warrants exist. The exhibits are the ground truth.

Convertible notes

The latest 10-Q/10-K instance document could not be checked just now, so nothing is shown rather than guessed. Try again shortly.

Registrations and offerings

Registered offering capacity on live registrations: $250.0Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted

F-3Aug 26, 2025$250.0M registeredfiling →
F-3Feb 5, 2025no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

Last 12 months: 2 executed · 1 registered.

EXECUTEDJan 9, 2026Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5 →
EXECUTEDJan 7, 2026Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5 →
MARKETINGJan 7, 2026Free-writing prospectus — offering being marketedFWP →
MARKETINGJan 7, 2026Free-writing prospectus — offering being marketedFWP →
EFFECTIVESep 2, 2025SEC declared a registration effective — selling can beginEFFECT →
REGISTEREDAug 26, 2025F-3 registration — capacity to sell shares, not a sale yetF-3 →
UPDATEFeb 14, 2025Prospectus update — often a resale registration, not necessarily new capital424B3 →
EFFECTIVEFeb 14, 2025SEC declared a registration effective — selling can beginEFFECT →
REGISTEREDFeb 5, 2025F-3 registration — capacity to sell shares, not a sale yetF-3 →

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full DRUG workspace